Studybox Research 510(k) Clinical Studies

Group A Streptococcus Rapid Antigen Test

Clinical and analytical performance to support substantial equivalence.

Studybox

510(k) Clinical Studies

Rapid strep A antigen tests are among the most-run waived tests in the country, and their clinical studies follow a well-worn design: patients with sore throat are enrolled, two throat swabs are collected simultaneously using a dual-swab technique, one is tested on the device by the site and the other goes to culture or a molecular comparator. The choice of comparator matters more than it used to, because molecular tests detect more positives than culture, and a device compared to culture will show different performance than the same device compared to NAAT.

Pediatric enrollment dominates because pharyngitis in school-age children is where group A streptococcus is most common, and the period from late fall through spring supplies most of the positives. Carriage without disease is a known confounder: a positive culture in a carrier still counts as a positive for study purposes, which is one reason these studies enroll symptomatic patients only.

Analyte: Group A streptococcal (Streptococcus pyogenes) cell wall carbohydrate antigen
Therapeutic area: Infectious Disease
Specimens: Oropharyngeal (Throat) Swab
Intended-use settings: urgent care, physician office, pharmacy, emergency department
Operators: Medical assistants, nurses and other non-laboratory staff in physician offices, urgent care centers and pharmacies with waived certificates.
Comparator: Typically bacterial culture on blood agar with confirmatory identification of beta-hemolytic group A streptococcus; an FDA-cleared group A streptococcus nucleic acid test is increasingly used as the comparator or for discordant resolution.

510(k) Studies specifics

What Changes for This Assay on This Pathway.

The protocol must declare whether culture or a cleared NAAT is the primary comparator; sensitivity against culture is typically higher than against NAAT, and reviewers expect the labeling to state which comparator was used.
Dual-swab collection with a documented, consistent technique is the accepted way to show that the device and comparator saw equivalent material; a sequential-swab design invites questions about specimen bias.
Discordant resolution by a second method is typically pre-specified and reported, but the primary analysis uses the primary comparator without resolution.

Endpoints the study must support

Sensitivity and specificity (or positive and negative percent agreement) against the culture or molecular comparator, with 95% confidence intervals
Performance in children and adults separately, and by clinical presentation where a clinical score is collected
Invalid rate and inter-operator agreement in waived settings

Enrollment realities

Driven by the number of culture- or NAAT-positive symptomatic patients, which depends on pediatric volume during strep season; adult positives are less frequent and accrue more slowly. Dual-swab collection failures and inadequate swabs are a predictable loss. Group A streptococcal pharyngitis peaks in late fall through spring in temperate U.S. regions, with low summer incidence.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Group A Streptococcus Rapid Antigen Test Study Questions.

01 Who operates the group a streptococcus rapid antigen test in a 510(k) studies study?

Medical assistants, nurses and other non-laboratory staff in physician offices, urgent care centers and pharmacies with waived certificates.

02 What is the comparator for a group a streptococcus rapid antigen test study?

Typically bacterial culture on blood agar with confirmatory identification of beta-hemolytic group A streptococcus; an FDA-cleared group A streptococcus nucleic acid test is increasingly used as the comparator or for discordant resolution.

03 What drives enrollment for a group a streptococcus rapid antigen test study?

Let's talk IVD research

Planning a group a streptococcus rapid antigen test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.